REPORT ID 6522

United States Chemotherapy Induced Peripheral Neuropathy Treatment Market Report 2017

Publish Date
26-Dec-17
Pages
116
Format
Electronic (PDF)

In this report, the United States Chemotherapy Induced Peripheral Neuropathy Treatment market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022.

Geographically, this report splits the United States market into seven regions:
    The West
    Southwest
    The Middle Atlantic
    New England
    The South
    The Midwest
with sales (volume), revenue (value), market share and growth rate of Chemotherapy Induced Peripheral Neuropathy Treatment in these regions, from 2012 to 2022 (forecast).

United States Chemotherapy Induced Peripheral Neuropathy Treatment market competition by top manufacturers/players, with Chemotherapy Induced Peripheral Neuropathy Treatment sales volume, price, revenue (Million USD) and market share for each manufacturer/player; the top players including
    Achelios Therapeutics Inc
    Advinus Therapeutics Ltd
    Apollo Endosurgery Inc
    Aptinyx Inc
    Asahi Kasei Pharma Corp
    Can-Fite BioPharma Ltd
    Celgene Corp
    DermaXon LLC
    Eisai
    Immune Pharmaceuticals Inc
    INSYS Therapeutics Inc
    Kineta Inc
    KPI Therapeutics Inc
    Krenitsky Pharmaceuticals Inc
    MAKScientific LLC
    Metys Pharmaceuticals AG
    Midatech Pharma US Inc
    Mundipharma International Ltd
    Nemus Bioscience Inc
    Neurocentrx Pharma Ltd
    Panacea Pharmaceuticals Inc
    PeriphaGen Inc
    PharmatrophiX Inc
    PledPharma AB
    Sova Pharmaceuticals Inc
    Virobay Inc
    WEX Pharmaceuticals Inc

On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, primarily split into
    APX-3330
    BR-297
    Cannabidiol
    Dimiracetam
    Others
On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate for each application, including
    Clinic
    Hospital
    Others

If you have any special requirements, please let us know and we will offer you the report as you want.

 
			   
Table of Contents

United States Chemotherapy Induced Peripheral Neuropathy Treatment Market Report 2017
1 Chemotherapy Induced Peripheral Neuropathy Treatment Overview
    1.1 Product Overview and Scope of Chemotherapy Induced Peripheral Neuropathy Treatment
    1.2 Classification of Chemotherapy Induced Peripheral Neuropathy Treatment by Product Category
        1.2.1 United States Chemotherapy Induced Peripheral Neuropathy Treatment Market Size (Sales Volume) Comparison by Type (2012-2022)
        1.2.2 United States Chemotherapy Induced Peripheral Neuropathy Treatment Market Size (Sales Volume) Market Share by Type (Product Category) in 2016
        1.2.3 APX-3330
        1.2.4 BR-297
        1.2.5 Cannabidiol
        1.2.6 Dimiracetam
        1.2.7 Others
    1.3 United States Chemotherapy Induced Peripheral Neuropathy Treatment Market by Application/End Users
        1.3.1 United States Chemotherapy Induced Peripheral Neuropathy Treatment Market Size (Consumption) and Market Share Comparison by Application (2012-2022)
        1.3.2 Clinic
        1.3.3 Hospital
        1.3.4 Others
    1.4 United States Chemotherapy Induced Peripheral Neuropathy Treatment Market by Region
        1.4.1 United States Chemotherapy Induced Peripheral Neuropathy Treatment Market Size (Value) Comparison by Region (2012-2022)
        1.4.2 The West Chemotherapy Induced Peripheral Neuropathy Treatment Status and Prospect (2012-2022)
        1.4.3 Southwest Chemotherapy Induced Peripheral Neuropathy Treatment Status and Prospect (2012-2022)
        1.4.4 The Middle Atlantic Chemotherapy Induced Peripheral Neuropathy Treatment Status and Prospect (2012-2022)
        1.4.5 New England Chemotherapy Induced Peripheral Neuropathy Treatment Status and Prospect (2012-2022)
        1.4.6 The South Chemotherapy Induced Peripheral Neuropathy Treatment Status and Prospect (2012-2022)
        1.4.7 The Midwest Chemotherapy Induced Peripheral Neuropathy Treatment Status and Prospect (2012-2022)
    1.5 United States Market Size (Value and Volume) of Chemotherapy Induced Peripheral Neuropathy Treatment (2012-2022)
        1.5.1 United States Chemotherapy Induced Peripheral Neuropathy Treatment Sales and Growth Rate (2012-2022)
        1.5.2 United States Chemotherapy Induced Peripheral Neuropathy Treatment Revenue and Growth Rate (2012-2022)

2 United States Chemotherapy Induced Peripheral Neuropathy Treatment Market Competition by Players/Suppliers
    2.1 United States Chemotherapy Induced Peripheral Neuropathy Treatment Sales and Market Share of Key Players/Suppliers (2012-2017)
    2.2 United States Chemotherapy Induced Peripheral Neuropathy Treatment Revenue and Share by Players/Suppliers (2012-2017)
    2.3 United States Chemotherapy Induced Peripheral Neuropathy Treatment Average Price by Players/Suppliers (2012-2017)
    2.4 United States Chemotherapy Induced Peripheral Neuropathy Treatment Market Competitive Situation and Trends
        2.4.1 United States Chemotherapy Induced Peripheral Neuropathy Treatment Market Concentration Rate
        2.4.2 United States Chemotherapy Induced Peripheral Neuropathy Treatment Market Share of Top 3 and Top 5 Players/Suppliers
        2.4.3 Mergers & Acquisitions, Expansion in United States Market
    2.5 United States Players/Suppliers Chemotherapy Induced Peripheral Neuropathy Treatment Manufacturing Base Distribution, Sales Area, Product Type

3 United States Chemotherapy Induced Peripheral Neuropathy Treatment Sales (Volume) and Revenue (Value) by Region (2012-2017)
    3.1 United States Chemotherapy Induced Peripheral Neuropathy Treatment Sales and Market Share by Region (2012-2017)
    3.2 United States Chemotherapy Induced Peripheral Neuropathy Treatment Revenue and Market Share by Region (2012-2017)
    3.3 United States Chemotherapy Induced Peripheral Neuropathy Treatment Price by Region (2012-2017)

4 United States Chemotherapy Induced Peripheral Neuropathy Treatment Sales (Volume) and Revenue (Value) by Type (Product Category) (2012-2017)
    4.1 United States Chemotherapy Induced Peripheral Neuropathy Treatment Sales and Market Share by Type (Product Category) (2012-2017)
    4.2 United States Chemotherapy Induced Peripheral Neuropathy Treatment Revenue and Market Share by Type (2012-2017)
    4.3 United States Chemotherapy Induced Peripheral Neuropathy Treatment Price by Type (2012-2017)
    4.4 United States Chemotherapy Induced Peripheral Neuropathy Treatment Sales Growth Rate by Type (2012-2017)

5 United States Chemotherapy Induced Peripheral Neuropathy Treatment Sales (Volume) by Application (2012-2017)
    5.1 United States Chemotherapy Induced Peripheral Neuropathy Treatment Sales and Market Share by Application (2012-2017)
    5.2 United States Chemotherapy Induced Peripheral Neuropathy Treatment Sales Growth Rate by Application (2012-2017)
    5.3 Market Drivers and Opportunities

6  United States Chemotherapy Induced Peripheral Neuropathy Treatment Players/Suppliers Profiles and Sales Data
    6.1 Achelios Therapeutics Inc
        6.1.1 Company Basic Information, Manufacturing Base and Competitors
        6.1.2 Chemotherapy Induced Peripheral Neuropathy Treatment Product Category, Application and Specification
            6.1.2.1 Product A
            6.1.2.2 Product B
        6.1.3 Achelios Therapeutics Inc Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue, Price and Gross Margin (2012-2017)
        6.1.4 Main Business/Business Overview
    6.2 Advinus Therapeutics Ltd
        6.2.2 Chemotherapy Induced Peripheral Neuropathy Treatment Product Category, Application and Specification
            6.2.2.1 Product A
            6.2.2.2 Product B
        6.2.3 Advinus Therapeutics Ltd Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue, Price and Gross Margin (2012-2017)
        6.2.4 Main Business/Business Overview
    6.3 Apollo Endosurgery Inc
        6.3.2 Chemotherapy Induced Peripheral Neuropathy Treatment Product Category, Application and Specification
            6.3.2.1 Product A
            6.3.2.2 Product B
        6.3.3 Apollo Endosurgery Inc Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue, Price and Gross Margin (2012-2017)
        6.3.4 Main Business/Business Overview
    6.4 Aptinyx Inc
        6.4.2 Chemotherapy Induced Peripheral Neuropathy Treatment Product Category, Application and Specification
            6.4.2.1 Product A
            6.4.2.2 Product B
        6.4.3 Aptinyx Inc Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue, Price and Gross Margin (2012-2017)
        6.4.4 Main Business/Business Overview
    6.5 Asahi Kasei Pharma Corp
        6.5.2 Chemotherapy Induced Peripheral Neuropathy Treatment Product Category, Application and Specification
            6.5.2.1 Product A
            6.5.2.2 Product B
        6.5.3 Asahi Kasei Pharma Corp Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue, Price and Gross Margin (2012-2017)
        6.5.4 Main Business/Business Overview
    6.6 Can-Fite BioPharma Ltd
        6.6.2 Chemotherapy Induced Peripheral Neuropathy Treatment Product Category, Application and Specification
            6.6.2.1 Product A
            6.6.2.2 Product B
        6.6.3 Can-Fite BioPharma Ltd Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue, Price and Gross Margin (2012-2017)
        6.6.4 Main Business/Business Overview
    6.7 Celgene Corp
        6.7.2 Chemotherapy Induced Peripheral Neuropathy Treatment Product Category, Application and Specification
            6.7.2.1 Product A
            6.7.2.2 Product B
        6.7.3 Celgene Corp Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue, Price and Gross Margin (2012-2017)
        6.7.4 Main Business/Business Overview
    6.8 DermaXon LLC
        6.8.2 Chemotherapy Induced Peripheral Neuropathy Treatment Product Category, Application and Specification
            6.8.2.1 Product A
            6.8.2.2 Product B
        6.8.3 DermaXon LLC Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue, Price and Gross Margin (2012-2017)
        6.8.4 Main Business/Business Overview
    6.9 Eisai
        6.9.2 Chemotherapy Induced Peripheral Neuropathy Treatment Product Category, Application and Specification
            6.9.2.1 Product A
            6.9.2.2 Product B
        6.9.3 Eisai Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue, Price and Gross Margin (2012-2017)
        6.9.4 Main Business/Business Overview
    6.10 Immune Pharmaceuticals Inc
        6.10.2 Chemotherapy Induced Peripheral Neuropathy Treatment Product Category, Application and Specification
            6.10.2.1 Product A
            6.10.2.2 Product B
        6.10.3 Immune Pharmaceuticals Inc Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue, Price and Gross Margin (2012-2017)
        6.10.4 Main Business/Business Overview
    6.11 INSYS Therapeutics Inc
    6.12 Kineta Inc
    6.13 KPI Therapeutics Inc
    6.14 Krenitsky Pharmaceuticals Inc
    6.15 MAKScientific LLC
    6.16 Metys Pharmaceuticals AG
    6.17 Midatech Pharma US Inc
    6.18 Mundipharma International Ltd
    6.19 Nemus Bioscience Inc
    6.20 Neurocentrx Pharma Ltd
    6.21 Panacea Pharmaceuticals Inc
    6.22 PeriphaGen Inc
    6.23 PharmatrophiX Inc
    6.24 PledPharma AB
    6.25 Sova Pharmaceuticals Inc
    6.26 Virobay Inc
    6.27 WEX Pharmaceuticals Inc

7 Chemotherapy Induced Peripheral Neuropathy Treatment Manufacturing Cost Analysis
    7.1 Chemotherapy Induced Peripheral Neuropathy Treatment Key Raw Materials Analysis
        7.1.1 Key Raw Materials
        7.1.2 Price Trend of Key Raw Materials
        7.1.3 Key Suppliers of Raw Materials
        7.1.4 Market Concentration Rate of Raw Materials
    7.2 Proportion of Manufacturing Cost Structure
        7.2.1 Raw Materials
        7.2.2 Labor Cost
        7.2.3 Manufacturing Expenses
    7.3 Manufacturing Process Analysis of Chemotherapy Induced Peripheral Neuropathy Treatment

8 Industrial Chain, Sourcing Strategy and Downstream Buyers
    8.1 Chemotherapy Induced Peripheral Neuropathy Treatment Industrial Chain Analysis
    8.2 Upstream Raw Materials Sourcing
    8.3 Raw Materials Sources of Chemotherapy Induced Peripheral Neuropathy Treatment Major Manufacturers in 2016
    8.4 Downstream Buyers

9 Marketing Strategy Analysis, Distributors/Traders
    9.1 Marketing Channel
        9.1.1 Direct Marketing
        9.1.2 Indirect Marketing
        9.1.3 Marketing Channel Development Trend
    9.2 Market Positioning
        9.2.1 Pricing Strategy
        9.2.2 Brand Strategy
        9.2.3 Target Client
    9.3 Distributors/Traders List

10 Market Effect Factors Analysis
    10.1 Technology Progress/Risk
        10.1.1 Substitutes Threat
        10.1.2 Technology Progress in Related Industry
    10.2 Consumer Needs/Customer Preference Change
    10.3 Economic/Political Environmental Change

11 United States Chemotherapy Induced Peripheral Neuropathy Treatment Market Size (Value and Volume) Forecast (2017-2022)
    11.1 United States Chemotherapy Induced Peripheral Neuropathy Treatment Sales Volume, Revenue Forecast (2017-2022)
    11.2 United States Chemotherapy Induced Peripheral Neuropathy Treatment Sales Volume Forecast by Type (2017-2022)
    11.3 United States Chemotherapy Induced Peripheral Neuropathy Treatment Sales Volume Forecast by Application (2017-2022)
    11.4 United States Chemotherapy Induced Peripheral Neuropathy Treatment Sales Volume Forecast by Region (2017-2022)

12 Research Findings and Conclusion

13 Appendix
    13.1 Methodology/Research Approach
        13.1.1 Research Programs/Design
        13.1.2 Market Size Estimation
        13.1.3 Market Breakdown and Data Triangulation
    13.2 Data Source
        13.2.1 Secondary Sources
        13.2.2 Primary Sources
    13.3 Disclaimer